Rely on GSK to provide the only flu vaccine that offers the same dose (0.5-mL) for a broad age range of patients, aged 6 months and older.1,2

3 ways to order or prebook

Call 1-855-475-4QIV (4748)

 
 

Contact your GSK Vaccines Sales Representative

Presentation

FLULAVAL QUADRIVALENT is available in1,3:

Product Shot 1

0.5-mL single-dose prefilled syringes (package of 10)

  • Thimerosal free
  • Disposable
  • Packaged without needles
  • CPT code 90686
Product Shot 2

5-mL multidose vials containing 10 doses (0.5-mL each)

  • Contains Thimerosal
  • Multidose vials should be discarded 28 days after first use
  • CPT code 90688
 

All trademarks are the property of their respective owners.

Indication

FLULAVAL QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLULAVAL QUADRIVALENT is approved for use in persons aged 6 months and older.

Important Safety Information for FLULAVAL QUADRIVALENT

  • Do not administer FLULAVAL QUADRIVALENT to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine
  • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLULAVAL QUADRIVALENT should be based on careful consideration of the potential benefits and risks
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including FLULAVAL QUADRIVALENT. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • If FLULAVAL QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons
  • In clinical trials with FLULAVAL QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were muscle aches, headache, fatigue, and arthralgia. In children 6 through 35 months of age, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 3 through 17 years of age, the most common solicited local adverse reaction was pain. In children 3 through 4 years of age, the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 5 through 17 years of age, the most common solicited systemic adverse reactions were muscle aches, fatigue, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLULAVAL QUADRIVALENT for other potential adverse reactions and events)
  • Vaccination with FLULAVAL QUADRIVALENT may not result in protection in all vaccine recipients

Please see full Prescribing Information for FLULAVAL QUADRIVALENT.

View all references.

 

819254R0 September 2017